These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9360083)

  • 1. A thromboxane A2 synthetase inhibitor as an anticoagulant for left ventricular assist devices.
    Takahama T; Kanai F; Onishi K
    ASAIO J; 1997; 43(5):M452-6. PubMed ID: 9360083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined administration of protease inhibitor and thromboxane A2 synthetase inhibitor for anticoagulation of a left ventricular assist device.
    Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
    ASAIO Trans; 1990; 36(3):M141-4. PubMed ID: 2252644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ideal anticoagulation for use with a left ventricular assist device.
    Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
    ASAIO J; 1995; 41(3):M779-82. PubMed ID: 8573913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of various anticoagulation therapies during use of a left ventricular assist device.
    Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
    ASAIO Trans; 1989; 35(3):426-9. PubMed ID: 2597495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation during use of a left ventricular assist device.
    Takahama T; Kanai F; Onishi K
    ASAIO J; 2000; 46(3):354-7. PubMed ID: 10826751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding.
    Kawai H; Tamao Y
    Thromb Res; 1995 Dec; 80(5):429-34. PubMed ID: 8588204
    [No Abstract]   [Full Text] [Related]  

  • 7. Danger of urokinase as an anticoagulant with left ventricular assist devices.
    Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
    ASAIO J; 1995; 41(3):M787-90. PubMed ID: 8573915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of anticoagulation therapy with an LVAD system.
    Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Furuse A; Asano K; Yoshitake T
    ASAIO Trans; 1987; 33(3):227-34. PubMed ID: 3118913
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical assessment of anticoagulation therapy during left ventricular assist with artificial heart: induction with protease inhibitor].
    Masuda M; Fukamachi K; Matsuzaki K; Asou T; Toshima Y; Kinoshita K; Mayumi H; Tominaga R; Miyamoto K; Komori M
    Kyobu Geka; 1989 Jun; 42(6):443-7. PubMed ID: 2506391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Argatroban, a selective thrombin inhibitor, for anticoagulant therapy during and following vascular surgery].
    Fuji H; Kurasako N; Takebayashi T; Tanaka T; Sakano S; Kosogabe Y; Mano M; Nagase H
    Masui; 1996 Oct; 45(10):1289-92. PubMed ID: 8937032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis.
    Badiye A; Hernandez GA; Chaparro S
    ASAIO J; 2014; 60(3):361-5. PubMed ID: 24614354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2.
    Motoyoshi M; Sugiyama M; Atomi Y; Kimura W; Nagawa H
    J Gastroenterol; 2006 Nov; 41(11):1094-8. PubMed ID: 17160520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
    Kato H; Emura S; Takeuchi N; Enoki M; Oogushi K; Takashima T; Ohmori K; Saito I
    J Int Med Res; 1997; 25(2):108-11. PubMed ID: 9100166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of a thromboxane-synthetase inhibitor in patients with chronic persistent coughing and no airwayhyperresponsiveness].
    Nishi K; Mizuguchi M; Tachibana H; Watanabe K; Ooka T; Fujimura M; Matsuda T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Sep; 35(9):927-33. PubMed ID: 9396248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
    Matsuo T; Koide M; Kario K
    Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture.
    Kawada T; Okada Y; Hoson M; Endo S; Yokoyama M; Kitanaka Y; Kimura K; Abe H; Yamate N
    Jpn J Thorac Cardiovasc Surg; 1999 Mar; 47(3):104-9. PubMed ID: 10226408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of anticoagulation in the critically ill patient.
    Toale KM
    Crit Care Nurs Clin North Am; 2013 Dec; 25(4):471-80, vi. PubMed ID: 24267283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argatroban Use in Pediatric Patients Supported by Paracorporeal Ventricular Assist Devices.
    Tuttle MG; Yan K; Zhang J; Niebler RA
    ASAIO J; 2024 Mar; 70(3):224-229. PubMed ID: 37934717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis].
    Niwa T; Nomura T; Ozawa Y; Maeda K; Shibata M
    Nihon Jinzo Gakkai Shi; 1987 Jun; 29(6):655-65. PubMed ID: 3682335
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experimental study on the prevention of vasospasm following subarachnoid hemorrhage by a thromboxane A2 synthetase inhibitor, OKY-046].
    Ohsugi S
    Nihon Geka Hokan; 1986 Mar; 55(2):297-305. PubMed ID: 3827476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.